Thank you for your question.
I apologize, but I'm going to answer in English to be more succinct and more accurate. My deep apologies, but I do this for the sake of accuracy and brevity.
Kawasaki disease is a rare disorder. It manifests in the heart as what's called coronary artery aneurysms and sometimes inflammation of the lining of the heart. We see this so rarely in Canada we don't have a good sense of the best therapies, particularly for the COVID version of a similar illness. The standard treatment would be steroid therapy, like a cortisone variance. We have absolutely no idea if this would work in COVID. From some early reports in China where it's been used, there's some limited evidence that this therapy may be harmful to COVID patients.
As a community we're unfortunately flying a little blind. We feel very bad that there are children who are affected, but these individuals are so infrequent that we really don't have any good data to help guide their therapy.
If I may be permitted, I think this is yet another example where to be able to give the best possible advice to our patients, whether it's pediatricians or adult physicians, it is absolutely imperative that we have access to the most comprehensive, accurate and real-time data on all aspects of COVID as we can so we can aggregate this information and not be dependent on our individual minor experience.